X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

ICYMI – 3 new reports show dramatic slowdown in medicine spending growth

By Holly Campbell  |    February 17, 2017
Newly released government actuary and pharmacy benefit manager data confirm previous projections of a significant decline in medicine spending growth. After accounting for discounts and rebates,...   Read More

What you don’t know about importation from Canada

By Allyson Funk  |    February 17, 2017
Proposals to allow the importation of prescription medicines from Canada ignore the dangerous threat to patients of counterfeit and adulterated medicines. What actually happens when a patient...   Read More

Biopharmaceutical industry’s success reducing disparities for African Americans

By Myisha Gatson  |    February 16, 2017
February is Black History Month, and here at PhRMA, we continue our decades-long commitment to reducing disparities in health care for minorities through developing and helping communities access...   Read More

Guest Post: Johnson and Johnson is celebrating outstanding scientists: Who will be next?

By Guest Contributor  |    February 15, 2017
As a health care company with the mission of bringing forward transformational solutions for patients and consumers, innovative scientific advances are the essence of our success. We believe that...   Read More

Watch: Biomarkers in drug development with Dr. Bernie Zeiher

By Andrew Powaleny  |    February 14, 2017
Biomarkers are powerful tools which are used by medical professionals in many ways, including in the diagnosis of disease, monitoring how a disease is progressing and, if a treatment is given, how...   Read More

Discovery of counterfeit hepatitis C drug is another example of why importation is bad for patients

By Nicole Longo  |    February 13, 2017
The manufacturing and trafficking of counterfeit drugs is not just a U.S. concern but a growing threat globally. Governments around the world are working together to try to prevent these fake...   Read More

Medicare Monday: What is IPAB, and why is it bad for patients?

By Nicole Longo  |    February 13, 2017
In 2017, the Independent Payment Advisory Board (IPAB)couldfinally go into effect and come between patients and their health care providers. This week, we’re looking into this dangerous body.     Read More

PhRMA urges USTR to protect American innovators abroad

By Mark Grayson  |    February 10, 2017
Yesterday, PhRMA submitted comments for the 2017 Special 301 Report the Office of the U.S. Trade Representative (USTR) will publish in April. The comments highlight serious intellectual property...   Read More

340B Spotlight: Audit findings show importance of increased oversight of 340B program

By Rebecca Davison  |    February 9, 2017
The 340B Drug Discount Program is an important component of the health care safety net, providing help to vulnerable or uninsured patients. However, with great power comes great responsibility,...   Read More

PhRMA CEO talks White House meeting, innovation & jobs with POLITICO’s Pulse Check

By Holly Campbell  |    February 9, 2017
Following the biopharmaceutical industry’s recent meeting with President  Donald J. Trump, PhRMA president and CEO Stephen J. Ubl joined Dan Diamond on POLITICO’s Pulse Check podcast to discuss...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates